Dendritic cell activation and T cell priming with adjuvant- and antigen-loaded oxidation-sensitive polymersomes

Biomaterials

Volumn 33, Issue 26, 2012, Pages 6211-6219

  Scott, Evan A ^a   Stano, Armando ^a   Gillard, Morgane ^a   Maio Liu, Alexandra C ^b   Swartz, Melody A ^a   Hubbell, Jeffrey A ^a  

^a EPFL   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Copolymer; Drug delivery; Immunomodulation; Self assembly

Indexed keywords

CROSS-PRIMING; CYTOKINE EXPRESSION; CYTOSOLS; DENDRITIC CELLS; ENDOSOMAL COMPARTMENTS; ENDOSOMES; HUMORAL IMMUNE RESPONSE; IMMUNE RESPONSE; IMMUNOMODULATION; NANO SCALE; OVALBUMINS; POLYMERSOMES; PROMOTING PROTEIN; SELF-ASSEMBLING BLOCK COPOLYMERS; SUBUNIT VACCINE; SURFACE MARKERS; T CELLS; TOLL-LIKE RECEPTORS; UP-REGULATION; VACCINE DELIVERY; VESICLE MEMBRANES; VIRAL INFECTIONS;

ANTIGENS; BLOCK COPOLYMERS; COPOLYMERS; CYTOLOGY; DEGRADATION; DISEASES; DRUG DELIVERY; IMMUNOLOGY; OXIDATION; POLYMERS; SELF ASSEMBLY; VACCINES;

CELLS;

CALCEIN; GARDIQUIMOD; INTERLEUKIN 12; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NANOCARRIER; OVALBUMIN; POLY(ETHYLENE GLYCOL) BLOCK POLY(PROPYLENE SULFIDE); RESIQUIMOD; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ARTICLE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL MATURATION; CONTROLLED STUDY; CROSS PRESENTATION; CYTOKINE RELEASE; CYTOSOL; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SOLUBILITY; ENCAPSULATION; ENDOSOME; OXIDATION; PRIORITY JOURNAL; T LYMPHOCYTE; UPREGULATION;

AMINOQUINOLINES; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; DENDRITIC CELLS; DRUG DELIVERY SYSTEMS; IMIDAZOLES; INTERLEUKIN-12; INTERLEUKIN-6; MICE; MICE, INBRED C57BL; POLYMERS; T-LYMPHOCYTES;

EID: 84862850542     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.04.060     Document Type: Article

References (44)

1. Hirosue S., Kourtis I.C., van der Vlies A.J., Hubbell J.A., Swartz M.A. Antigen delivery to dendritic cells by poly(propylene sulfide) nanoparticles with disulfide conjugated peptides: cross-presentation and t cell activation. Vaccine 2010, 28:7897-7906.
2. Tacken P.J., Zeelenberg I.S., Cruz L.J., van Hout-Kuijer M.A., van de Glind G., Fokkink R.G., et al. Targeted delivery of toll-like receptor ligands to human and mouse dendritic cells strongly enhances adjuvanticity. Blood 2011, 118:6836-6844.
3. Boudier A., Aubert-Pouessel A., Mebarek N., Chavanieu A., Quentin J., Martire D., et al. Development of tripartite polyion micelles for efficient peptide delivery into dendritic cells without altering their plasticity. J Control Release 2011, 154:156-163.
4. Yang D., Zhao Y., Guo H., Li Y., Tewary P., Xing G., et al. [gd@c(82) (oh) (22)](n) nanoparticles induce dendritic cell maturation and activate th1 immune responses. ACS Nano 2010, 4:1178-1186.
5. Stano A., van der Vlies A.J., Martino M.M., Swartz M.A., Hubbell J.A., Simeoni E. Pps nanoparticles as versatile delivery system to induce systemic and broad mucosal immunity after intranasal administration. Vaccine 2011, 29:804-812.
6. Sallusto F., Cella M., Danieli C., Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med 1995, 182:389-400.
7. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783-801.
8. Gunzer M., Riemann H., Basoglu Y., Hillmer A., Weishaupt C., Balkow S., et al. Systemic administration of a tlr7 ligand leads to transient immune incompetence due to peripheral-blood leukocyte depletion. Blood 2005, 106:2424-2432.
9. Savage P., Horton V., Moore J., Owens M., Witt P., Gore M.E. A phase i clinical trial of imiquimod, an oral interferon inducer, administered daily. Br J Cancer 1996, 74:1482-1486.
10. Villadangos J.A., Schnorrer P. Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo. Nat Rev Immunol 2007, 7:543-555.
11. Pratten M.K., Lloyd J.B. Pinocytosis and phagocytosis: the effect of size of a particulate substrate on its mode of capture by rat peritoneal macrophages cultured in vitro. Biochim Biophys Acta 1986, 881:307-313.
12. Kim H., Uto T., Akagi T., Baba M., Akashi M. Amphiphilic poly(amino acid) nanoparticles induce size-dependent dendritic cell maturation. Adv Funct Mater 2010, 20:3925-3931.
13. Bachmann M.F., Jennings G.T. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 2010, 10:787-796.
14. Reddy S.T., Rehor A., Schmoekel H.G., Hubbell J.A., Swartz M.A. In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. J Control Release 2006, 112:26-34.
15. Reddy S.T., van der Vlies A.J., Simeoni E., Angeli V., Randolph G.J., O'Neil C.P., et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol 2007, 25:1159-1164.
16. Hu Y., Litwin T., Nagaraja A.R., Kwong B., Katz J., Watson N., et al. Cytosolic delivery of membrane-impermeable molecules in dendritic cells using pH-responsive core-shell nanoparticles. Nano Lett 2007, 7:3056-3064.
17. Yuba E., Kojima C., Harada A., Tana Watarai S., Kono K. pH-sensitive fusogenic polymer-modified liposomes as a carrier of antigenic proteins for activation of cellular immunity. Biomaterials 2010, 31:943-951.
18. Cohen J.A., Beaudette T.T., Tseng W.W., Bachelder E.M., Mende I., Engleman E.G., et al. T-cell activation by antigen-loaded ph-sensitive hydrogel particles in vivo: the effect of particle size. Bioconjug Chem 2009, 20:111-119.
19. Savina A., Amigorena S. Phagocytosis and antigen presentation in dendritic cells. Immunol Rev 2007, 219:143-156.
20. Broaders K.E., Grandhe S., Frechet J.M. A biocompatible oxidation-triggered carrier polymer with potential in therapeutics. J Am Chem Soc 2011, 133:756-758.
21. Napoli A., Valentini M., Tirelli N., Muller M., Hubbell J.A. Oxidation-responsive polymeric vesicles. Nat Mater 2004, 3:183-189.
22. Massignani M., Lomas H., Battaglia G. Polymersomes: a synthetic biological approach to encapsulation and delivery. Adv Polym Sci 2010, 229:115-154.
23. Ahmed F., Pakunlu R.I., Brannan A., Bates F., Minko T., Discher D.E. Biodegradable polymersomes loaded with both paclitaxel and doxorubicin permeate and shrink tumors, inducing apoptosis in proportion to accumulated drug. J Control Release 2006, 116:150-158.
24. Smart T., Lomas H., Massignani M., Flores-Merino M.V., Perez L.R., Battaglia G. Block copolymer nanostructures. Nano Today 2008, 3:38-46.
25. Cerritelli S., O'Neil C.P., Velluto D., Fontana A., Adrian M., Dubochet J., et al. Aggregation behavior of poly(ethylene glycol-bl-propylene sulfide) di- and triblock copolymers in aqueous solution. Langmuir 2009, 25:11328-11335.
26. Blumenthal R., Henkart M., Steer C.J. Clathrin-induced pH-dependent fusion of phosphatidylcholine vesicles. J Biol Chem 1983, 258:3409-3415.
27. Zhou F., Watkins S.C., Huang L. Characterization and kinetics of mhc class I-restricted presentation of a soluble antigen delivered by liposomes. Immunobiology 1994, 190:35-52.
28. Liu G., Ma S., Li S., Cheng R., Meng F., Liu H., et al. The highly efficient delivery of exogenous proteins into cells mediated by biodegradable chimaeric polymersomes. Biomaterials 2010, 31:7575-7585.
29. Quer C.B., Marsden H.R., Romeijn S., Zope H., Kros A., Jiskoot W. Polymersomes enhance the immunogenicity of influenza subunit vaccine. Polym Chem (UK) 2011, 2:1482-1485.
30. Dubochet J., Adrian M., Chang J.J., Homo J.C., Lepault J., Mcdowall A.W., et al. Cryo-electron microscopy of vitrified specimens. Q Rev Biophys 1988, 21:129-228.
31. Lutz M.B., Kukutsch N., Ogilvie A.L., Rossner S., Koch F., Romani N., et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 1999, 223:77-92.
32. Discher B.M., Won Y.Y., Ege D.S., Lee J.C., Bates F.S., Discher D.E., et al. Polymersomes: tough vesicles made from diblock copolymers. Science 1999, 284:1143-1146.
33. Battaglia G., Ryan A.J. Pathways of polymeric vesicle formation. J Phys Chem B 2006, 110:10272-10279.
34. Kazzaz J., Singh M., Ugozzoli M., Chesko J., Soenawan E., O'Hagan D.T. Encapsulation of the immune potentiators mpl and rc529 in plg microparticles enhances their potency. J Control Release 2006, 110:566-573.
35. Singh M., Chakrapani A., O'Hagan D. Nanoparticles and microparticles as vaccine-delivery systems. Expert Rev Vaccines 2007, 6:797-808.
36. Kasturi S.P., Skountzou I., Albrecht R.A., Koutsonanos D., Hua T., Nakaya H.I., et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 2011, 470:543-547.
37. Savina A., Jancic C., Hugues S., Guermonprez P., Vargas P., Moura I.C., et al. Nox2 controls phagosomal pH to regulate antigen processing during crosspresentation by dendritic cells. Cell 2006, 126:205-218.
38. Lin M.L., Zhan Y., Villadangos J.A., Lew A.M. The cell biology of cross-presentation and the role of dendritic cell subsets. Immunol Cell Biol 2008, 86:353-362.
39. Flanary S., Hoffman A.S., Stayton P.S. Antigen delivery with poly(propylacrylic acid) conjugation enhances mhc-1 presentation and t-cell activation. Bioconjug Chem 2009, 20:241-248.
40. Rodriguez A., Regnault A., Kleijmeer M., Ricciardi-Castagnoli P., Amigorena S. Selective transport of internalized antigens to the cytosol for mhc class I presentation in dendritic cells. Nat Cell Biol 1999, 1:362-368.
41. Kovacsovics-Bankowski M., Rock K.L. A phagosome-to-cytosol pathway for exogenous antigens presented on mhc class I molecules. Science 1995, 267:243-246.
42. Saveanu L., Carroll O., Weimershaus M., Guermonprez P., Firat E., Lindo V., et al. Irap identifies an endosomal compartment required for mhc class I cross-presentation. Science 2009, 325:213-217.
43. Belizaire R., Unanue E.R. Targeting proteins to distinct subcellular compartments reveals unique requirements for mhc class I and II presentation. Proc Natl Acad Sci U S A 2009, 106:17463-17468.
44. Jurk M., Heil F., Vollmer J., Schetter C., Krieg A.M., Wagner H., et al. Human tlr7 or tlr8 independently confer responsiveness to the antiviral compound r-848. Nat Immunol 2002, 3:499.